2023
Coffee as chemoprotectant in fatty liver disease: caffeine-dependent and caffeine-independent effects
Dranoff J. Coffee as chemoprotectant in fatty liver disease: caffeine-dependent and caffeine-independent effects. AJP Gastrointestinal And Liver Physiology 2023, 324: g419-g421. PMID: 36976807, DOI: 10.1152/ajpgi.00026.2023.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsLiver diseaseLiver-related mortalityChronic liver diseaseFatty liver diseasePositive health outcomesPrimary active ingredientCoffee consumptionEpidemiological studiesHealth outcomesAdenosine receptorsBiological plausibilityDiseaseActive ingredientsPatientsAntagonistMortalityRecent publicationsReceptors
2022
Obesity, but not glycemic control, predicts liver steatosis in children with type 1 diabetes
Tas E, Bai S, Mak D, Diaz E, Dranoff J. Obesity, but not glycemic control, predicts liver steatosis in children with type 1 diabetes. Journal Of Diabetes And Its Complications 2022, 36: 108341. PMID: 36345110, DOI: 10.1016/j.jdiacomp.2022.108341.Peer-Reviewed Original ResearchMeSH KeywordsBody Mass IndexChildCholesterol, HDLCross-Sectional StudiesDiabetes Mellitus, Type 1HumansLiverNon-alcoholic Fatty Liver DiseaseObesityConceptsNonalcoholic fatty liver diseaseBody mass indexMajor risk factorType 1 diabetesHDL ratioHDL cholesterolLiver diseaseClinical parametersRisk factorsCAP scoresDiagnostic performanceReceiver operator curve analysisCommon liver diseaseFatty liver diseaseNon-diabetic childrenNon-obese subjectsFindings of childrenCross-sectional studyNAFLD statusClinical characteristicsGlycemic controlObese groupObese subjectsFurther workupMass indexReview of existing evidence demonstrates that methotrexate does not cause liver fibrosis
Cheema HI, Haselow D, Dranoff JA. Review of existing evidence demonstrates that methotrexate does not cause liver fibrosis. Journal Of Investigative Medicine 2022, 70: 1452-1460. PMID: 36002175, DOI: 10.1136/jim-2021-002206.Peer-Reviewed Original ResearchConceptsChronic liver diseaseLiver diseaseLiver fibrosisLiver injuryPre-existing chronic liver diseaseNon-alcoholic fatty liver diseaseLong-term methotrexateMeta-analysis portionProgressive liver injurySerial liver biopsiesFatty liver diseaseAdvanced liver fibrosisCare of patientsMetabolic liver diseaseNon-invasive assessmentComprehensive literature searchAssessment of injuryMethotrexate doseAdvanced fibrosisCommon indicationDirect causeLiver biopsyTherapeutic dosesRisk factorsInclusion criteria
2020
Fibroblast Growth Factor-21 to Adiponectin Ratio: A Potential Biomarker to Monitor Liver Fat in Children With Obesity
Tas E, Bai S, Ou X, Mercer K, Lin H, Mansfield K, Buchmann R, Diaz EC, Oden J, Børsheim E, Adams SH, Dranoff J. Fibroblast Growth Factor-21 to Adiponectin Ratio: A Potential Biomarker to Monitor Liver Fat in Children With Obesity. Frontiers In Endocrinology 2020, 11: 654. PMID: 33071964, PMCID: PMC7533567, DOI: 10.3389/fendo.2020.00654.Peer-Reviewed Original ResearchMeSH KeywordsAdiponectinAdolescentBiomarkersChildFemaleFibroblast Growth FactorsHumansLiverMagnetic Resonance ImagingMaleNon-alcoholic Fatty Liver DiseaseObesityTriglyceridesConceptsNon-alcoholic fatty liver diseaseMagnetic resonance imagingIntrahepatic triglyceridesPercent changePotential biomarkersClinical weight loss programSerum fibroblast growth factorFibroblast growth factor 21Liver fat percentFatty liver diseaseWeight loss programGrowth factor 21Non-invasive biomarkersFibroblast growth factorCourse diseaseSerum FGF21Adiponectin ratioFinal visitAdiponectin levelsLiver biopsyLiver diseaseObese childrenLoss programLiver fatFactor 21